FDG PET/CT显示双侧腋窝淋巴结高摄取,由同期接种COVID-19加强针和季节性流感疫苗所致
一例48岁右侧口咽鳞状细胞癌女性患者在接受放疗后行FDG PET/CT,显示原发肿瘤代谢完全缓解,但双侧腋窝出现良性形态的高摄取淋巴结,归因于近期接种辉瑞-BioNTech加强针和流感疫苗后的反应性改变。健康机构推荐同期接种COVID-19和流感疫苗,ComFluCOV试验表明耐受良好且不降低对任一疫苗的免疫应答。
要点
- 同期接种COVID-19加强针和流感疫苗可引起双侧腋窝淋巴结反应性高摄取,形态呈良性。
- 健康机构推荐同期接种COVID-19和流感疫苗,ComFluCOV试验显示耐受良好且免疫应答未降低。
- 此类疫苗相关淋巴结摄取预计在未来数月会更常见。
核心结论
- 同期接种COVID-19加强针和季节性流感疫苗可导致双侧腋窝淋巴结呈良性形态的反应性FDG高摄取,预计未来数月会更常见。
研究设计与样本
- 病例报告:一例48岁右侧口咽鳞状细胞癌女性患者,放疗后行FDG PET/CT评估疗效。
主要发现
- 放疗后FDG PET/CT显示原发肿瘤代谢完全缓解。
- incidental发现双侧腋窝淋巴结高摄取,形态呈良性,结论为对近期接种辉瑞-BioNTech加强针和流感疫苗的反应性改变。
关键数值与推荐
- ComFluCOV试验表明同期接种COVID-19和流感疫苗耐受良好,且不降低对任一疫苗的免疫应答。
临床怎么用
- 健康机构推荐同期接种COVID-19和流感疫苗以保护高风险人群并减轻医疗系统负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In an attempt to protect the high-risk demographic and reduce burden on health care systems, concomitant administration of COVID-19 and influenza vaccines has been recommended by health bodies. The ComFluCOV trial indicates this is well tolerated with no reduction in immune response to either vaccine. A 48-year-old woman with right oropharyngeal squamous cell carcinoma underwent postradiotherapy FDG PET/CT, which demonstrated complete metabolic response. Incidental avid bilateral axillary lymphadenopathy of benign configuration was noted and concluded to be reactive in response to recent Pfizer-BioNTech booster and influenza vaccination. This is expected to be seen more frequently over the coming months.
引用
- Nawwar AA, Searle J, Lyburn ID, et al. Bilateral Avid Axillary Nodes on FDG PET/CT Due to Concurrent Booster COVID-19 Immunization and Seasonal Influenza Vaccination. Clin Nucl Med. 2022. PMID: 35384871. doi:10.1097/RLU.0000000000004169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。